22-02-16
Member news
Pharmaclear PP Seal RP 62 EU introduces doubly effective counterfeit protection for pharmaceuticals
UPM Raflatac has launched a new label face in EMEIA as part of a security range for prescription and high-risk over-the-counter pharmaceuticals. The destructible Pharmaclear PP Seal adds a second layer of security to the tamper-evident functionality of the RP 62 EU adhesive, by preventing label misappropriation on counterfeit products.
Pharmaclear PP Seal RP 62 EU is designed for use as a sealing label on cardboard packages with water-based varnishes. The RP 62 EU adhesive provides tamper-evidence by producing visible cardboard tear upon attempted removal, while the new Pharmaclear PP Seal label face visibly stretches, effectively destroying the label.
The label face and adhesive combination also supports compliance with the Falsified Medicines Directive (2011/62/EU) by incorporating tamper-evident features as described in the new CEN standard EN 16679: 'Packaging - Tamper verification features for medicinal product packaging'. This EU-delegated regulation on safety features is now published, with the deadline for meeting EN 16679 requirements set for 9 February 2019 in the majority of EU member states.
"Pharmaclear PP Seal strengthens our existing product range based on the RP 62 EU adhesive. The new product offers even wider features to better secure the supply chain, blends easily with existing package designs and branding, and fulfils the requirements of EN 16679 as the pharmaceutical industry seeks solutions ahead of the three-year deadline," comments Markku Pietarinen, Labelling Solutions Manager, Pharmaceutical labelling, UPM Raflatac EMEIA.
Pharmaclear PP Seal RP 62 EU is designed for use as a sealing label on cardboard packages with water-based varnishes. The RP 62 EU adhesive provides tamper-evidence by producing visible cardboard tear upon attempted removal, while the new Pharmaclear PP Seal label face visibly stretches, effectively destroying the label.
The label face and adhesive combination also supports compliance with the Falsified Medicines Directive (2011/62/EU) by incorporating tamper-evident features as described in the new CEN standard EN 16679: 'Packaging - Tamper verification features for medicinal product packaging'. This EU-delegated regulation on safety features is now published, with the deadline for meeting EN 16679 requirements set for 9 February 2019 in the majority of EU member states.
"Pharmaclear PP Seal strengthens our existing product range based on the RP 62 EU adhesive. The new product offers even wider features to better secure the supply chain, blends easily with existing package designs and branding, and fulfils the requirements of EN 16679 as the pharmaceutical industry seeks solutions ahead of the three-year deadline," comments Markku Pietarinen, Labelling Solutions Manager, Pharmaceutical labelling, UPM Raflatac EMEIA.